Genomic Test May Spare More Patients With Node-Positive Breast Cancer From Chemo
Reducing Chemotherapy Use
The phase III OPTIMA trial was presented at the American Society of Clinical Oncology meeting, sparking discussion among experts about treatment decisions for high-risk early breast cancer. The trial's findings were shared on June 9, 2026. Researchers explored the use of the Prosigna genomic test.
The Prosigna test guides treatment decisions by identifying patients with node-positive breast cancer who may not benefit from chemotherapy. The OPTIMA trial investigated whether the test could safely spare some patients from chemotherapy. Experts weighed in on the trial's results, discussing the potential implications for patient care.
The trial's results showed that the Prosigna test can help identify patients with node-positive breast cancer who have a low risk of recurrence. By using the test, clinicians may be able to spare these patients from unnecessary chemotherapy. According to experts, this could lead to a significant reduction in chemotherapy use.
Can Genomic Tests Replace Traditional Methods?
Experts noted that the Prosigna test provides valuable information about a patient's risk of recurrence, allowing clinicians to make more informed treatment decisions. The test's results can help identify patients who are likely to benefit from chemotherapy, while also identifying those who may not need it.
The OPTIMA trial's findings raise questions about the role of genomic tests in breast cancer treatment. While traditional methods, such as clinical staging, have long been used to guide treatment decisions, genomic tests like Prosigna offer a more nuanced understanding of a patient's risk. Experts discussed the potential for genomic tests to become a standard tool in breast cancer care.
The OPTIMA trial's results are likely to have significant implications for patient care, potentially leading to a reduction in chemotherapy use and improved outcomes for patients with node-positive breast cancer. As clinicians begin to incorporate genomic tests like Prosigna into their practice, patients may benefit from more personalized and effective treatment.
Frequently Asked Questions
What is the Prosigna genomic test? The Prosigna test is a genomic test that helps identify patients with node-positive breast cancer who may not benefit from chemotherapy. It provides information about a patient's risk of recurrence.
How does the Prosigna test work? The test analyzes a tumor sample to determine its genetic characteristics, providing a more detailed understanding of a patient's risk.
Will the Prosigna test replace traditional methods? The Prosigna test is not intended to replace traditional methods, but rather to provide additional information to guide treatment decisions.